OncoLink Cancer Treatment and Resources
Link to OncoLink

Brachytherapy and Size of the Prostate

Ultima Vez Modificado: 16 de septiembre del 2007

Question

Dear OncoLink "Ask The Experts,"

Does the size of the prostate (e.g. greater than 90cc) automatically preclude brachytherapy?

Answer

Neha Vapiwala , MD, Senior Editor of OncoLink and Chief Resident in the Department of Radiation Oncology at the Hospital of the University of Pennsylvania, responds:

No, a large prostate does not automatically preclude brachytherapy as a treatment option. However, a patient with a large prostate may be asked to undergo a temporary course of medication (drugs such as Zoladex or Lupron) in order to reduce the prostate to a size more optimal for performing brachytherapy.

In most cases, this approach works, and the ideal brachytherapy volume is successfully achieved. Also, some centers are studying and using combination external beam radiation therapy and brachytherapy for large and/or more advanced stage prostate cancers.

Having said this, many practitioners believe that the ideal prostate volume for immediate brachytherapy would be 40-50 cc or less. There are three reasons for this view:

  1. A larger prostate has a higher chance of urinary obstruction requiring catheterization after brachytherapy.
  2. Because the needles used for brachytherapy are all of the same standard size, it may be difficult or impossible to reach all the regions of a prostate that is too large with the needles that are available. A large prostate often also grows beyond the bony confines of the pelvis, so the bones may get in the way of the needles reaching all the necessary regions within the prostate.
  3. It can be more difficult to achieve a uniform dose distribution throughout the prostate if the prostate is too large. In other words, the odds of insufficient radiation dose to certain areas can be higher in a prostate that is extremely large.

OncoLink I wish u knew...

Dr. Glatstein shares some of the important lessons he has conveyed upon the many oncology professionals he has trained. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS